LPA Variants Are Associated With Residual Cardiovascular Risk in Patients Receiving Statins.

ABSTRACT:

Background

Coronary heart disease (CHD) is a leading cause of death globally. Although therapy with statins decreases circulating levels of low-density lipoprotein cholesterol and the incidence of CHD, additional events occur despite statin therapy in some individuals. The genetic determinants of this residual cardiovascular risk remain unknown.

Methods

We performed a 2-stage genome-wide association study of CHD events during statin therapy. We first identified 3099 cases who experienced CHD events (defined as acute myocardial infarction or the need for coronary revascularization) during statin therapy and 7681 controls without CHD events during comparable intensity and duration of statin therapy from 4 sites in the Electronic Medical Records and Genomics Network. We then so

SUBMITTER: Wei WQ 

PROVIDER: S-EPMC6202211 | biostudies-literature | 2018 Oct

REPOSITORIES: biostudies-literature